Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis.
Chester V OddisHoward E RocketteLei ZhuDiane C KoontzDavid LacomisSwamy VenturupalliSiamak Moghadam-KiaDana P AschermanLeslie CroffordMazen M DimachkieFloranne ErnsteDavid GazeleyGalina MarderRohit AggarwalPublished in: ACR open rheumatology (2022)
Tocilizumab was safe and well tolerated but did not meet the primary or secondary efficacy outcomes in refractory DM and PM in this 24-week phase 2B study.